Welcome to our dedicated page for Maravai Lifesciences Holdings SEC filings (Ticker: MRVI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) SEC filings page provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents include annual and quarterly reports, current reports on Form 8-K, and other filings that detail Maravai’s financial performance, segment results, governance changes, and material corporate events.
As a registrant on the Nasdaq Global Select Market, Maravai files periodic reports that describe its operations in two primary segments: Nucleic Acid Production and Biologics Safety Testing. In its Forms 10-K and 10-Q, investors can review revenue by segment, gross profit, operating expenses, net loss, and non-GAAP reconciliations for measures such as Adjusted EBITDA and Adjusted Net Loss. These filings also explain adjustments related to items like goodwill impairment, acquisition integration costs, stock-based compensation, restructuring charges, and other non-recurring items.
Current reports on Form 8-K are particularly important for tracking material events at Maravai. Recent 8-K filings referenced in public information cover topics such as the announcement of quarterly financial results, organizational restructuring and workforce reductions, leadership transitions including the appointment of a new Chief Executive Officer and Chief Financial Officer, and changes in the composition of the Board of Directors. These documents also describe estimated restructuring costs and the terms of executive employment and separation arrangements.
Through this page, users can follow Maravai’s regulatory history, including disclosures about its Class A common stock registered on the Nasdaq Global Select Market under the symbol MRVI and its principal location in San Diego, California. AI-powered tools on the platform can help summarize lengthy filings, highlight key sections on segment performance and restructuring, and surface information on governance changes and other events disclosed in Forms 8-K, enabling a more efficient review of Maravai’s SEC reporting.